Bold redefinition: early cancer screening must evolve from reactive checks to proactive prevention. Human Longevity, Inc. (HLI), a global pioneer in precision health and longevity medicine, has broadened its $1 million cancer pledge to include colon cancer. This expansion reinforces the company’s commitment to detecting disease earlier when treatment is most effective and lives can be saved. HLI remains the only longevity-focused health company offering a cancer pledge of this kind, reflecting confidence in a holistic, integrated strategy to cancer prevention. The pledge provides up to $1 million in clinical support for eligible members diagnosed with late-stage colon cancer while they are actively enrolled in HLI’s Executive Health Program or one of more than 100 affiliated Longevity Programs.
Colon cancer ranks among the world’s leading causes of cancer-related deaths, yet it is highly preventable with early detection. Too many diagnoses occur after symptoms emerge and the disease has advanced. Traditional screening often follows age-based schedules and routine procedures like colonoscopy, which identify tumors only after they form. No single test can reliably detect colon cancer in its early, molecular stages or in regions that are harder to visualize. HLI’s pledge tackles these gaps by shifting screening upstream toward true prevention through a multi-faceted approach.
Whole genome sequencing plays a pivotal role in uncovering both inherited single-gene risk and complex polygenic risk for colon cancer, often years before symptoms or visible disease appear. When paired with imaging, biomarker analysis, and molecular screening, this genomic insight contributes to a comprehensive, personalized risk profile rather than relying solely on age guidelines.
The strength of this integrated approach was demonstrated by a recent client case. A patient had a normal colonoscopy, yet positive results from both the GRAIL blood test and the Cologuard stool DNA test prompted further evaluation, which revealed cancer in the appendix—a region not always thoroughly assessed during routine procedures. This underscores the value of using diverse tools together to form a clearer picture of risk.
HLI delivers one of the most comprehensive early cancer-detection platforms available by combining:
- Whole genome sequencing for monogenic and polygenic risk assessment
- Advanced full-body MRI and targeted imaging
- Multi-cancer blood screening, such as GRAIL
- Non-invasive stool DNA testing, such as Cologuard
- Continuous biomarker monitoring
- Advanced AI analytics for personalized health insights
By integrating these technologies into a unified health profile, HLI enables earlier risk identification, more accurate detection, and timely clinical action—helping members maximize their chances to prevent colon cancer or catch it early.
How the Initiative Works
Members receive personalized screening plans through HLI’s Executive Health Program or 100+ Longevity Programs. Participants diagnosed with late-stage colon cancer during active membership are eligible for up to $1 million in coordinated clinical support, including specialist consultations and treatment navigation.
“Our mission is to detect colon cancer before it becomes life-threatening,” said Dr. Wei-Wu He, Executive Chairman of Human Longevity. “Early detection isn’t about relying on a single test—it’s about integrating accurate clinical insights across multiple tools to give our members the strongest possible chance to prevent disease or catch it early.”
About Human Longevity
Founded in 2013, Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, AI, and multimodal diagnostics to extend human healthspan. Through its flagship Executive Health Program and 100+ Longevity Programs, HLI delivers comprehensive, data-driven evaluations aimed at identifying and preventing disease long before symptoms arise. To learn more or enroll, visit www.humanlongevity.com.
Media contact: [emailaddress]
